4th Quarter - Report

RYAN MACKINNON VASAPOLI AND BERZOK, LLP for GENENTECH

Period 4th Quarter 2012 Filed Jan 24, 2013 Signed by Mr. Thomas M. Ryan, Managing Partner

Official filing
Firm
RYAN MACKINNON VASAPOLI AND BERZOK, LLP
Client
GENENTECH
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics. Concerns regarding Meicare payment policies for Biologics.

LobbyistCovered position, as disclosed
MATTHEW BERZOK LD, Chief Counsel, LA Rep. Stupak & Deutsch
NICK KOLOVOS LA Rep. Anna Eshoo (D-California)
JEFF MACKINNON LD & LA Rep. Joe Barton (R-Texas)
JEFFERY C MORTIER Staff on Energy & Commerce Committee
THOMAS RYAN —
JOSEPH V VASAPOLI Min. Counsel, Energy&Comm, Special Asst. DOE

Contacted: Executive Office of the President (EOP); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 1 (112th)

Pharmacy PHA

Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

LobbyistCovered position, as disclosed
MATTHEW BERZOK LD, Chief Counsel, LA Rep. Stupak & Deutsch
NICK KOLOVOS LA Rep. Anna Eshoo (D-California)
JEFF MACKINNON LD & LA Rep. Joe Barton (R-Texas)
JEFFERY C MORTIER Staff on Energy & Commerce Committee
THOMAS RYAN —
JOSEPH V VASAPOLI Min. Counsel, Energy&Comm, Special Asst. DOE

Contacted: Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Health Issues HCR

Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines. Implementation of the follow-on biologics provisions in P.L. 111-148- "Patient Protection and Affordable Care Act".

LobbyistCovered position, as disclosed
MATTHEW BERZOK LD, Chief Counsel, LA Rep. Stupak & Deutsch
NICK KOLOVOS LA Rep. Anna Eshoo (D-California)
JEFF MACKINNON LD & LA Rep. Joe Barton (R-Texas)
JEFFERY C MORTIER Staff on Energy & Commerce Committee
THOMAS RYAN —
JOSEPH V VASAPOLI Min. Counsel, Energy&Comm, Special Asst. DOE

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.